CDNA

In the past six months, CareDx's stock has experienced several significant events. CareDx announced strong first-quarter 2026 financial results, with total revenue increasing 39% year-over-year and raised its full-year 2026 revenue guidance. CareDx entered into a definitive agreement to acquire Naveris, Inc. CareDx announced an agreement to divest its Lab Products business to EuroBio Scientific. The Board authorized a new common stock repurchase program of up to $100 million over 24 months. CEO John Walter Hanna, Jr. sold 10,282 shares of the company's stock. Wall Street Zen upgraded CareDx (CDNA) from a "buy" to a "strong-buy."